Platform
Company
Coagulation
Review status
Currently under review
Pending specialist review and validation.
The Factor VIII Preliminary test is a screening assay that estimates the activity of factor VIII, a clotting protein also called antihemophilic factor. Your plasma is challenged in a clotting test to see how effectively factor VIII supports clot formation. The result offers an initial view of whether factor VIII function appears reduced, within expected limits, or higher than expected.
Clinicians often order this test when investigating easy bruising, nosebleeds, heavy menstrual bleeding, excessive bleeding after procedures, or an unexplained prolongation of a clotting time. It can also be used to get a quick sense of response to treatments intended to raise factor VIII activity.
Factor VIII is essential for normal clotting. Low functional activity can suggest hemophilia A, carrier status, von Willebrand disease that affects factor VIII stability, or an acquired problem such as an inhibitor that blocks factor VIII. Identifying reduced activity helps guide choices about bleeding precautions, perioperative planning, and the need for factor replacement or other therapies.
Higher factor VIII activity can occur with inflammation, stress, pregnancy, or estrogen therapy, and has been associated with increased risk of blood clots in some situations. Your healthcare team considers this test together with your symptoms, medical history, medications, and other lab results to decide next steps.
If your result is lower than expected, your clinician may repeat the test to confirm it and may order more specific studies, such as a full factor VIII activity assay, a mixing study, testing for inhibitors, von Willebrand testing, or genetic studies. A low result does not by itself determine the cause; it is a clue that needs context and confirmation.
If your result is higher than expected, it may reflect temporary conditions such as acute illness, surgery, pregnancy, or hormone use. Your clinician may recheck levels when you are well, review risk factors for clotting, and consider whether any changes in medications or follow-up are appropriate. Borderline or unexpected results are often repeated, and management decisions are based on the overall clinical picture rather than a single value.
Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.
Factor VIII is labile. Prolonged tourniquet time, difficult draws, underfilled citrate tubes, delayed plasma separation, or improper storage can falsely lower or alter results. Prompt, proper processing is important.
Factor VIII behaves as an acute phase reactant. Illness, infection, surgery, vigorous exercise, or smoking can raise activity temporarily and may mask an underlying deficiency.
Desmopressin and factor concentrates can raise factor VIII. Heparin, warfarin, and direct oral anticoagulants may interfere with clot-based assays and complicate interpretation. Always share a full medication list.
Pregnancy and estrogen-containing therapies often increase factor VIII activity. Results in these settings are interpreted with caution and may be rechecked after delivery or after hormonal changes.
Hemophilia A and carrier states lower factor VIII activity. Autoimmune inhibitors or acquired conditions can also reduce activity. Follow-up testing, such as mixing studies and inhibitor assays, helps distinguish causes.
References